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Abstract
IMPORTANCE The presence of high-risk human papillomavirus (HPV) has been associated with a
favorable outcome in Barrett high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC).
Nevertheless, the prognostic significance of other HPV-related biomarkers (ie, retinoblastoma
protein [pRb], cyclin D1 [CD1], minichromosomemaintenance protein [MCM2] and Ki-67)
is unknown.
OBJECTIVE To examine the association between HPV-related biomarkers and survival in adult
patients with Barrett HGD and EAC.
DESIGN, SETTING, ANDPARTICIPANTS This retrospective case-control study examined the
hypothesis that the HPV-related cell cycle markers (pRb, CD1, and Ki-67) and the viral surrogate
marker (MCM2) may be associated with a favorable prognosis in Barrett HGD and EAC. Pretreatment
biopsies were used for HPV DNA determination via polymerase chain reaction and
immunohistochemistry for the HPV-related biomarkers. Recruitment of patients occurred in
secondary and tertiary referral centers, with 151 patients assessed for eligibility. The study period was
from December 1, 2002, to November 28, 2017, and the dates of analysis were from September 9,
2011, to November 28, 2017.
MAINOUTCOMESANDMEASURES Disease-free survival and overall survival.
RESULTS Of 151 patients assessed for eligibility, 9 were excluded. Among the 142 patients with
Barrett HGD or EAC (126 [88.7%]men; mean [SD] age, 66.0 [12.1] years; 142 [100%] white), 37 were
HPV positive and 105 were HPV negative. No association with disease-free survival was noted for
pRb, CD1, Ki-67, andMCM2. In regard to overall survival, only low expression of CD1 had a favorable
prognosis (hazard ratio [HR], 0.53; 95%CI, 0.30-0.95; adjusted P = .03). All the biomarkers stratified
by HPV status showed significant associations with survival. Patients with HPV-positive,
low-expression pRb esophageal tumors were associated with a significantly improved disease-free
survival compared with the HPV-negative, high-expression Rb tumors (HR, 0.33; 95% CI, 0.12-0.93;
adjusted P = .04). Similarly, HPV-positive, low-expression CD1 was associated with a significantly
favorable disease-free survival (HR, 0.26; 95% CI, 0.09-0.76; adjusted P = .01), as was HPV-positive,
high-expressionMCM2 (HR, 0.27; 95%CI, 0.09-0.78; adjusted P = .02). In regard to overall survival,
HPVwas significantly associated onlywith low CD1 (HR, 0.38; 95%CI, 0.15-0.94; adjusted P = .04).
CONCLUSIONS ANDRELEVANCE This study’s findings suggest that low expression of CD1 appears
to be an independent prognostic marker in Barrett HGD and EAC. Human papillomavirus positivity
in combination with pRb, CD1, MCM2, and Ki-67 was associated with a survival benefit in esophageal
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Abstract (continued)
tumors. These findings suggest the possibility of personalization of therapy for Barrett HGD and EAC
based on viral status.
JAMA Network Open. 2020;3(2):e1921189. doi:10.1001/jamanetworkopen.2019.21189
Introduction
Transcriptionally active high-risk-human papillomavirus (HPV) infection has been associated with
Barrett dysplasia and esophageal adenocarcinoma (EAC).1,2 Nevertheless, studies showing no
association with HPV and Barrett dysplasia and EAC exist. Reasons for the negative findings include
poor tissue classification, suboptimal testing methods, small sample sizes, racial and geographic
variations, and the use of metaplastic tissue that is not associated with the virus.3-7 However, a
systematic review published before these studies reported HPV prevalence rates of 35% in 174
patients with EAC.8 Another systematic review that included 19 studies found that the pooled
prevalence of HPV in EACwas 13%. The authors suggested that the low prevalence rate may have
been caused by small sample sizes and compromised detectionmethods.9
Human papilloma virus–positive Barrett high-grade dysplasia (HGD) and EAC seem to be
distinct biological entities with a favorable prognosis compared with HPV-negative esophageal
tumors andmay benefit from treatment deescalation.10,11 A previous study demonstrated superior
disease-free survival for HPV, transcriptionally active virus, E6 and E7 messenger RNA (mRNA), and
high p16 expression, but not p53.11 Likewise, HPV-induced head and neck squamous cell carcinomas
are a distinct subset with a more favorable prognosis compared with HPV-negative
oropharyngeal cancers.12,13
Transcriptionally active HPV (DNA positive determined by polymerase chain reaction [PCR] and
the presence of1 of 2 markers of biological activity, ie, E6/E7mRNA and/or p16INK4A) involvement
in Barrett dysplasia and EAC is characterized by wild-type p53 and aberrations of the retinoblastoma
protein (pRb) pathway (downregulation of the pRb as well as upregulation of p16INK4A).14 We
investigated the prognostic significance of other cell-cycle markers, in particular, those related to
HPV: pRb, CD1, minichromosomemaintenance protein (MCM2), and Ki-67. Retinoblastoma protein,
MCM2, and Ki-67 are considered surrogate markers of HPV oncogene expression (E6/E7, which are 2
viral proteins required for malignant cell transformation in HPV-driven cancers) when present in the
upper layers of cervical lesions.15,16 A combination of Ki-67 and HPV status has been demonstrated to
provide apparently superior prognostic information comparedwith HPV status alone in HPV-induced
head and neck squamous cell carcinomas.17 Ki-67 is a cellular marker for proliferation and is
expressed during all active phases of the cell cycle (G1, S, G2, andM) but is absent in the resting G0
phase. The pRb is a tumor-suppressor protein that exerts negative (checkpoint) control of the cell
cycle and reduces excessive growth; pRb is degraded by the viral E7 oncoprotein with
downregulation of pRb and CD1 and upregulation of p16INK4A.18-20
Increased expression of CD1 (a protein required for progression through the G1 phase of the cell
cycle) has been documented in EAC.21,22 An earlier study investigating amolecular signature in virally
associated esophageal cancer and its precursor lesion reported no association between CD1 andHPV
DNA-positive andmRNA-positive (predominantly low-grade) Barrett dysplasia and EAC.14
Nevertheless, we did not investigate the prognostic significance of CD1 in Barrett dysplasia and EAC
irrespective of HPV status. There are conflicting reports on the use of CD1 as a marker for other
HPV-associated lesions,23,24 such as head and neck cancers and cervical cancer.25
Minichromosomemaintenance protein is a family of 6 related proteins (MCM2-MCM7) that are
involved in the initiation of DNA replication. Increased levels of MCM indicate proliferation of
malignant cells as expressed in several types of cancers and is possibly more accurate than Ki-67 as a
marker of proliferation.26,27 Persistent expression of MCM2, MCM5, and Ki-67may be diagnostic
markers in Barrett dysplasia.28 Furthermore, MCMs can predict tumor progression and thus are
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prognostic markers. Significant expression of MCM2 has been reported in Barrett dysplasia and EAC
and in Barrett esophagus at subsequent risk of disease progression.29 Moreover, patients with EAC
who have greater than 70% expression levels for MCM4 (high expression) had reduced survival
compared with those with less than or equal to 70% nuclear staining for MCM4 (low expression).30
Abnormal expression of MCM2 in HPV-associated cervical cancer and cervical intraepithelial
neoplasia has resulted in its use as a screening test for these lesions.31,32
Given the differential mutational andmolecular landscape between HPV-positive and
HPV-negative esophageal dysplastic and adenocarcinoma lesions, we hypothesized that viral-related
cell-cycle proteins (eg, CD1 and pRb) and surrogate markers of viral E6 and E7 oncogene expression
(MCM2 and Ki-67) may vary in these 2 biologically distinct tumors.10,14 Furthermore, we investigated
the association between HPV DNA status and the prognostic value, if any, of the aforementioned
biomarkers to elucidate a potential interaction of the virus.
Methods
Study Population
In this retrospective case-control study, eligible patients were those with Barrett HGD or EAC
undergoing treatment with endotherapy (endoscopic mucosal resection and/or radiofrequency
ablation) or esophagectomywith or without neoadjuvant chemoradiotherapy as previously
described.11 The enrollment period was fromDecember 1, 2002, to November 28, 2017. Study
institutions included a tertiary referral center (Bankstown-Lidcombe Hospital, Sydney, New South
Wales, Australia; n = 139) and a regional health care center Launceston General Hospital, Launceston,
Tasmania, Australia; n = 3). Demographic (age, sex, bodymass index) and clinical (ever smoked,
excess alcohol use, proton pump inhibitor use, and resectionmargin status) data were obtained from
a prospectively maintained database. Inclusion and exclusion criteria have been previously
documented.14 Staging was performed as per the 7th edition of the AJCC Cancer Staging Manual by
the American Joint Committee on Cancer.33 Oral and written consent was obtained from participants
prior to the investigation. This study was approved by the Human Research Ethics Committee,
Tasmania and SouthWestern Sydney Local Health Network. The participants did not receive financial
compensation. This study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline for case-control studies.
Laboratory Studies
Detection of HPV in genomic DNA extracted from fresh-frozen or formalin-fixed biopsy tissue was
performed by nested PCR amplification of a conserved viral L1 gene using MY09 andMY11 and GP5+
and GP6+ primers for both high-risk and low-risk HPV as previously published.1 To minimize
contamination, separate rooms were used for reaction preparation, template handling, performing
nested reactions, and post-PCR analysis. Routine decontamination by UV irradiation was performed
in the DNA-free PCR hood before each run. To guard against systematic contamination of PCR
reagent, appropriate positive (HPV16-positive cervical cancer) and negative (deionized water and
PCRmaster mix without template) controls were included in each step of the PCR process. The HPV
genotypes were determined by sequencing.1 Real-time PCR assays measuring HPV E6 and E7 copy
numbers using genotype-specific HPV-16 and HPV-18 primers were used to ascertain viral load.2
Expression of pRb, CD1, MCM2, and Ki-67 was assessed by immunohistochemistry on formalin-
fixed, paraffin-embedded tissue (EnVision FLEXMini Kits; Dako). Expression of pRb and CD1 was
evaluated as previously described.14 For both Ki-67 andMCM2 after pretreatment, antigen retrieval
was carried out using a high pH target retrieval solution for 20 minutes in a 98 °C water bath. After
cooling, endogenous peroxidase was blocked by peroxidase-blocking reagent; sections were then
incubated with primary antibodies monoclonal mouse antihuman Ki-67 antigen (1:100, CloneMIB-1;
Dako) and anti-MCM2 rabbit polyclonal antibody (1:100, ab31159; Abcam) for 20 minutes at room
temperature. The sections were washed with 1X wash buffer and incubated with secondary antibody
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(FLEX/HRP; EnVision) for 20minutes at room temperature. DAB substrate + chromogen was used
for color development. Sections were counterstained with hematoxylin for better visualization of
tissuemorphologic characteristics. Negative control was included by substitution of primary and
secondary antibodies with human serum. A tissue section of cancer known to be positive for the
particular proteinmarker studiedwas included in each run. Normal esophageal squamous tissue from
a lesion-free patient was used as a staining reference for all 4 cellular protein markers.14 The
microtome blade was replaced with sectioning of each new specimen to prevent cross-
contamination.
All immunohistochemical scoring of slides was independently performed by 2 experienced
gastrointestinal pathologists (T.Y. and L.D.S.) blinded to the virologic status and clinical outcome of
the patients. For ease of evaluation, only 2 categories of staining were applied to all of the biomarkers
(ie, high or low expression). For pRb and CD1 nuclear staining of at least moderate intensity in a
minimum of 25% of the esophageal lesional cells was considered high expression. Less than 25%
staining of pRb and cyclin D1 was scored as low expression.14,34 For Ki-67, a nuclear staining
percentage greater than 20%was considered increased proliferation. Less than 20%was scored as
0, 21% to 50%was considered moderate proliferation with a score of 1, and more than 50%was
considered strong proliferation and scored as 2.35 For the purposes of this study, a score of 1 or 2 was
considered Ki-67-positive and a score of 0 was considered Ki-67 negative. TheMCM2was scored 0
for lack of staining, 1 for up to 30% positive staining of the nucleus, and 2 for greater than 30%
positive staining of the nucleus. Any diffuse nuclear staining greater than 30%was considered high
expression and less than or equal to 30% as low expression.28
Statistical Analysis
The primary end points were disease-free survival from the time of diagnosis to the date of the first
failure (local, regional, or distant) and overall survival, defined as the time between diagnosis and the
date of death or last follow-up. Differences between HPV-positive vs HPV-negative cases in regard
to baseline characteristics were assessed using the 2-sample t test for comparing the mean values
between the 2 groups in regard to all numeric data. The association between the binary
measurements in the viral-positive and viral-negative groups was evaluated using χ2 analysis.
Survival analysis was conducted using the Kaplan-Meier method to estimate the disease-free survival
and overall survival of the combination of HPV status and the 4 biomarkers (ie, pRb, CD1,MCM2, and
Ki-67). Cox proportional hazards regressionmodels were used to estimate the importance of these
variables for disease-free survival and overall survival after adjusting for age, sex, body mass index,
ever smoked, excess alcohol use, proton pump inhibitor use, nonsteroidal anti-inflammatory drug
use, statin use, and surgical or endoscopic mucosal resectionmargin status. Any interaction between
HPV status and the 4 biomarkers was explored, followed by stratified analysis as appropriate.
Laboratory and data analysis were performed from September 9, 2011, to November 28, 2017.
All statistical tests were performed using SAS software, version 9.4 (SAS Institute Inc), and the
level of significance was set at P < .05.
Results
Patient Characteristics
One hundred fifty-one patients were assessed for eligibility; 9 were excluded because they had
gastric carcinoma. Therefore, 142 individuals with Barrett HGD or EACwere included in the study. Of
these, 126 patients (88.7%)weremen and themean (SD) agewas 66.0 (12.1) years; all of the patients
were white. Themean (SD) follow-up time was 33.4 (28.0) months (range, 2-159months) for all
patients and 43.8 (29.4) months (range, 3-159months) for surviving patients. Among the 37 HPV
DNA-positive lesions (HPV16, n = 33; HPV18, n = 1; HPV6, n = 1; and HPV11, n = 2), median viral load
was 0.1 copy per 10-cell genomic DNA (0-1.12 copies per 10-cell genome). These data are depicted in
eTable 1 in the Supplement and in a previous publication.11 There were no significant differences in
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treatment (ie, endotherapy, esophagectomy, chemotherapy, and radiotherapy) between patients
with HPV-positive and HPV-negative Barrett HGD or EAC.
Biomarker Status
All 142 patients were analyzed for HPV DNA, pRb, CD1, MCM2, and Ki-67 (eFigure 1 and eFigure 2 in
the Supplement). Downregulation of pRbwas present in 18 of 37 patients (48.6%) with HPV-positive
Barrett HGD or EAC as opposed to 35 of 105 patients (33.3%)with HPV-negative Barrett HGD or EAC
(P = .10) (eTable 1 in the Supplement). Similarly, low expression of CD1 was not statistically
significantly different betweenHPV-positive (22 of 37 [59.5%]) andHPV-negative (54 of 105 [51.4%])
EAC (P = .40). Again, therewas no appreciable difference in Ki-67 expression betweenHPV-positive
(31 of 37 [83.8%]) and HPV-negative (79 of 105 [75.2%]) EAC (P = .28). In contrast, high MCM2
expression was significantly lower in HPV-positive Barrett HGD and EAC (15 of 37 [40.5%]) as
opposed to HPV-negative (70 of 105 [66.7%]) (P = .005).
On univariate ormultivariate analysis, none of themarkers (low-expression pRb, low-expression
CD1, Ki-67–positive, or high-expressionMCM2) had any association with disease-free survival
(Table 1). In regard to overall survival, only low expression of CD1 had a favorable prognosis even after
adjusting for confounders (hazard ratio [HR], 0.53; 95% CI, 0.30-0.95; P = .03) (Table 1).
Biomarkers Stratified byHPV Status
The pRb, CD1, MCM2 and Ki-67markers stratified by HPV status had a significant association with
disease-free survival on univariate analysis. Onmultivariate analysis, only pRb, CD1 andMCM2
stratified by HPV status maintained a significant association with diseases-free survival (Table 2 and
Figure 1). Thus, patients with EAC that was HPV-positive with low pRb expression were associated
with significantly improved disease-free survival compared with HPV-negative, high-expression pRb
on univariate analysis (HR, 0.29; 95% CI, 0.10-0.82; P = .02) and even after adjusting for age, sex,
bodymass index, ever smoked, excess alcohol use, and resectionmargin (HR, 0.33; 95% CI,
0.12-0.93; adjusted P = .04). In the case of HPV-positive, high-expression pRb, there was improved
disease-free survival on univariate analysis, but not after adjustment for confounders (Table 2).
Similarly, onmultivariate analysis, HPV-positive, low-expression CD1 was associated with a
significantly favorable disease-free survival (HR, 0.26; 95% CI, 0.09-0.76; adjusted P = .01), as was
HPV-positive, high-expression MCM2 (HR, 0.27; 95% CI, 0.09-0.78; adjusted P = .02) (Table 2).
Human papillomavirus–positive, Ki-67-positive HGD/EAC was associated with improved prognosis
on univariate analysis (HR, 0.47; 95% CI, 0.23-0.96; P = .04), but not after adjustment for
confounders (HR, 0.49; 95% CI, 0.23-1.07; adjusted P = .07).
In regard to overall survival, HPV had a significant association only with low expression of CD1,
which was associated with significant improvements in survival both on univariate analysis and after
Table 1. Log-Rank andMultivariate Disease-Free Survival and Overall Survival Analysis
Characteristic
Disease-Free Survival Overall Survival
Model 1a Model 2b Model 1a Model 2b
HR (95% CI)
Unadjusted
P Value HR (95% CI)
Adjusted
P Value HR (95% CI)
Unadjusted
P Value HR (95% CI)
Adjusted
P Value
Low pRb expression 0.85 (0.52-1.40) .53 0.88 (0.52-1.49) .64 1.22 (0.73-2.06) .45 1.39 (0.79-2.43) .25
Low CD1 expression 0.77 (0.48-1.23) .28 0.75 (0.44-1.27) .29 0.58 (0.34-0.97) .04 0.53 (0.30-0.95) .03
Ki-67–positive 0.73 (0.43-1.24) .24 0.81 (0.45-1.46) .48 0.90 (0.49-1.65) .73 1.22 (0.61-2.46) .58
High-expression MCM2 1.53 (0.93-2.52) .10 1.37 (0.80-2.34) .25 1.15 (0.68-1.94) .61 1.04 (0.58-1.85) .90
Abbreviations: CD1, cyclin D1; HR, hazard ratio; MCM,minichromosomemaintenance
protein; pRb, retinoblastoma protein.
a Model 1 was a univariate analysis of each characteristic with disease-free survival.
b In model 2, each characteristic was analyzed separately, using multivariate Cox
proportional hazards regression, adjusted for the following covariates: age, sex, body
mass index, ever smoked, excess alcohol use, proton pump inhibitor use, nonsteroidal
anti-inflammatory drug use, statin use, and R0 resectionmargin.
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adjustment for confounders (HR, 0.38; 95% CI, 0.15-0.94; adjusted P = .04) (Table 3 and Figure 2).
None of the other biomarkers stratified for HPV status was associated with overall survival.
Biomarkers Stratified byHPV Status and Survival
Human papillomavirus status again had a positive association with CD1, pRb, andMCM2 regarding
disease-free survival, disease relapse and progression, and disease-specific death. Human
papillomavirus-positive, low- or high-expression pRb Barrett HGD and EACwere associated with
substantially improved disease-free survival (41.2 months vs 39.5 months vs 25.5 months vs 23.4
months, respectively; P = .03), reduced progression and recurrence (4 patients vs 5 patients vs 20
patients vs 41 patients, respectively; P = .006), distant metastases (3 patients vs 0 patients vs 13
patients vs 16 patients, respectively; P = .02) and death due to EAC (2 patients vs 3 patients vs 15
patients vs 23 patients, respectively; P = .049) compared with HPV-negative, low-or high-expression
pRb lesions (eTable 2 in the Supplement). Overall, HPV-positive, low-expression or high-expression
CD1 Barrett HGD and EAC lesionswere associatedwith superior disease-free survival (38.9months vs
42.5 months vs 26.3 months vs 21.7 months, respectively; P = .02), reduced recurrence or
progression (4 patients vs 5 patients vs 31 patients vs 30 patients, respectively; P = .004), distant
metastases (2 patients vs 1 patient vs 12 patients vs 17 patients, respectively; P = .049) and death due
to EAC (2 patients vs 3 patients vs 16 patients vs 22 patients, respectively; P = .024) compared with
HPV-negative, low-or high-expression CD1 (eTable 3 in the Supplement). Patients with HPV-positive,
Table 2. Log-Rank andMultivariate Disease-Free Survival Analysis of Biomarkers Stratified by HPV Status
Biomarker
Disease-Free Survival
Model 1a Model 2b
HR (95% CI)
Unadjusted
P Value Adjusted HR (95% CI)
Adjusted
P Value
Retinoblastoma Protein
HPV-negative
High expression 1 [Reference] NA 1 [Reference] NA
Low expression 1.01 (0.59-1.72) .98 1.11 (0.62-2.00) .73
HPV-positive
High expression 0.37 (0.15-0.94) .04 0.37 (0.13-1.05) .06
Low expression 0.29 (0.10-0.82) .02 0.33 (0.12-0.93) .04
Cyclin D1
HPV-negative
High expression 1 [Reference] NA 1 [Reference] NA
Low expression 0.83 (0.50-1.37) .46 0.89 (0.51-1.54) .67
HPV-positive
High expression 0.40 (0.16-1.04) .06 0.41 (0.14-1.22) .11
Low expression 0.23 (0.08-0.64) .005 0.26 (0.09-0.76) .01
Minichromosome Maintenance Protein 2
HPV-negative
High expression 1 [Reference] NA 1 [Reference] NA
Low expression 0.79 (0.46-1.37) .40 0.94 (0.52-1.69) .83
HPV-positive
High expression 0.23 (0.08-0.65) .005 0.27 (0.09-0.78) .02
Low expression 0.41 (0.16-1.04) .06 0.43 (0.15-1.24) .12
Ki-67
HPV-negative
Positive 1 [Reference] NA 1 [Reference] NA
Negative 1.62 (0.94-2.78) .08 1.45 (0.79-2.65) .23
HPV-positive
Positive 0.47 (0.23-0.96) .04 0.49 (0.23-1.07) .07
Negative NA NA NA NA
Abbreviations: HR, hazard ratio; HPV, human
papillomavirus; NA, not applicable.
a Model 1 was a univariate analysis on each
characteristic with disease-free survival.
b In model 2, each characteristic was analyzed
separately using multivariate Cox proportional
hazards regression, adjusted by the following
covariates: age, sex, bodymass index, ever smoked,
excess alcohol use, and R0 resectionmargin.
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high-expressionMCM2 had better clinical outcomes in terms of recurrence or progression and death
due to EAC compared with HPV-negative, high-expressionMCM2 (4 patients vs 43 patients;
P = .003; and 2 patients vs 28 patients; P = .035, respectively) (eTable 4 in the Supplement). For
Ki-67–negative esophageal tumors, HPV positivity was associated with superior disease-free and
overall survival compared with HPV-negative/Ki-67–negative lesions (53.2 months vs 18.8months;
P = .009; and 54.8months vs 25.8months; P = .03, respectively) (eTable 5 in the Supplement).
Discussion
In this study of 142 patients with Barrett HGD or EAC, we retrospectively examined the prognostic
value of cell-cycle markers that have been previously documented to be associated with
HPV-associated cancers. This study enabled us to examine howmolecular aberrations,
clinicopathologic characteristics, and effect size modification of HPVmay be associated with survival
in this cohort of patients with EAC.
Figure 1. Disease-Free Survival Among PatientsWith High-Grade Dysplasia or Esophageal Adenocarcinoma as a Function
of Human Papillomavirus (HPV)–Stratified Biomarkers
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Rephrase as follows: Of 142 patients with either high-grade Barrett dysplasia or
esophageal adenocarcinoma, 37 were HPV positive and 105 were HPV negative. Of note,
HPV positive/low pRb (A), HPV positive/low CD1 (B), HPV positive/high MCM2 (C) and
HPV positive/Ki-67 negative (D) were associated with the best disease-free survival. CD1
indicates cyclin D1; HR, hazard ratio; MCM2,minichromosomemaintenance protein; and
pRb, retinoblastoma protein.
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The pRb, CD1, MCM2, and Ki-67 biomarkers were not independently associated with disease-
free survival. Regarding overall survival, only low CD1 expression was associated with a significantly
improved prognosis in patients with EAC. In this regard, a case-control analysis of CD1 overexpression
in Barrettmetaplasia has been associatedwith an increased risk of adenocarcinoma (odds ratio, 6.85;
95% CI, 1.57-29.91; P = .01).36
Human papillomavirus–positive status was associated with disease-free survival and
low-expression pRb, low-expression CD1, and high-expression MCM2. In regard to overall survival,
only low expression of CD1 had prognostic significance in Barrett HGD and EAC when stratified
according to HPV status. Low expression of pRb, low expression of CD1, and high expression of
MCM2were all associatedwith superior disease-free survival for HPV-positive tumors comparedwith
HPV negative esophageal lesions. Again, HPV stratification of low expression pRb, low-expression
CD1 and high expression MCM2 was significantly associated with outcomes pertaining to survival,
disease relapse and progression and disease-specific death.
The potential influence of HPV in association with other biomarkers and survival outcomes has
also been described in oropharyngeal squamous cell carcinomas.37 Hypoxia-inducible factor-1
transcription factor overexpression predicted worse survival in HPV-positive compared with
HPV-negative oropharyngeal head and neck squamous cell carcinomas. Similarly, it has been
reported that Ki-67 expression has improved prognostic significance when stratified according to
HPV status in HPV-induced head and neck squamous cell carcinomas.17 The best survival outcomes
Table 3. Log-Rank andMultivariate Overall Survival Analysis of Biomarkers Stratified by HPV Status
Biomarker
Overall Survival
Model 1a Model 2b
HR (95% CI)
Unadjusted
P Value Adjusted HR (95% CI)
Adjusted
P Value
Retinoblastoma Protein
HPV-negative
High expression 1 [Reference] NA 1 [Reference] NA
Low expression 1.34 (0.75-2.40) .33 1.78 (0.92-3.44) .09
HPV-positive
High expression 0.53 (0.21-1.38) .20 0.55 (0.19-1.59) .27
Low expression 0.67 (0.28-1.62) .37 0.72 (0.29-1.79) .48
Cyclin D1
HPV-negative
High expression 1 [Reference] NA 1 [Reference] NA
Low expression 0.54 (0.20-0.96) .03 0.56 (0.29-1.06) .07
HPV-positive
High expression 0.43 (0.17-1.13) .09 0.47 (0.16-1.43) .18
Low expression 0.37 (0.15-0.89) .03 0.38 (0.15-0.94) .04
Minichromosome Maintenance Protein 2
HPV-negative
High expression 1 [Reference] NA 1 [Reference] NA
Low expression 0.69 (0.36-1.31) .25 0.81 (0.41-1.61) .55
HPV-positive
High expression 0.44 (0.19-1.06) .07 0.45 (0.18-1.12) .09
Low expression 0.52 (0.20-1.34) .18 0.60 (0.20-1.75) .35
Ki-67
HPV-negative
Positive 1 [Reference] NA 1 [Reference] NA
Negative 1.14 (0.59-2.21) .69 0.79 (0.37-1.67) .53
HPV-positive
Positive 0.57 (0.27-1.19) .13 0.53 (0.24-1.16) .11
Negative 0.50 (0.12-2.07) .34 0.41 (0.09-1.78) .23
Abbreviations: HPV, human papillomavirus; HR,
hazard ratio; NA, not applicable.
a Model 1 was a univariate analysis on each
characteristic with disease-free survival.
b In model 2, each characteristic was analyzed
separately, using multivariate Cox proportional
hazards regression, adjusted for the following
covariates: age, sex, bodymass index, ever smoked,
excess alcohol use, and R0 resectionmargin.
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were identified in HPV-positive, Ki-67–negative tumors and the worst in HPV-negative, Ki-67–
positive HPV-induced head and neck squamous cell carcinomas. In this cohort of patients with
HGD/EAC, those with HPV-positive/Ki-67–negative tumors were associated with superior disease-
free survival and overall survival compared with individuals possessing HPV-negative/Ki-67–negative
esophageal lesions.
AlteredMCM2 expression signifies cell-cycle deregulation, which is necessary for the initiation
and progression of cancer. Human papillomavirus infection is responsible for overexpression of this
protein in cervical dysplasia, with consequent uncontrolled activation of gene transcription and
aberrant S-phase inductionmediated via the E2F transcription factor pathway.38
In our study, patients with HPV-positive, high-expressionMCM2 Barrett HGD and EACwere
associated with better clinical outcomes in terms of recurrence or progression and death due to EAC
compared with HPV-negative, high-expressionMCM2. Moreover, onmultivariable analysis,
HPV-positive/high-expressionMCM2 esophageal tumors had a superior disease-free survival as
compared with HPV-negative/high-expressionMCM2. Minichromosomemaintenance protein is
considered a surrogate marker of E6 and E7 expression, which are oncoproteins of high-risk
Figure 2. Overall Survival Among PatientsWith High-Grade Dysplasia or Esophageal Adenocarcinoma as a Function
of Human Papillomavirus (HPV)–Stratified Biomarkers
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Of 142 patients with either high-grade dysplasia or esophageal adenocarcinoma, 37 were
HPV positive and 105 were HPV negative. Of note, HPV positive/high pRb (A), HPV
positive/low CD1 (B), HPV positive/highMCM2 (C) and HPV positive/Ki-67 negative (D)
appeared to be associated with the best overall survival. Nevertheless, only the HPV
positive/low CD1 result reached statistical significance. CD1 indicates cyclin D1; HR,
hazard ratio; MCM2, minichromosomemaintenance protein; and pRb,
retinoblastoma protein.
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HPV.39,40 In this regard, a previous study demonstrated improved disease-free survival in
transcriptionally active HPV- and E6/E7-associated Barrett HGD and EAC.11
Proteolysis with consequent degradation and inactivation of pRb by the HPV E7 oncoprotein
causes reduced immunostaining of the protein in tumor tissue sections.20 In turn, pRb inactivation
causes increased expression of p16INK4A. Conversely, CD1 staining is reduced or absent because an
intact pRb is necessary for its expression.41 Upregulation of p16INK4A and downregulation of pRb are
cellular consequences of HPV transformation.14,24 Accordingly, CD1 mRNA has been shown to be
reduced or absent in HPV-induced oropharyngeal squamous cell carcinomas.19 Nevertheless, other
investigators have reported that low expression of CD1 is an unreliable marker for HPV-induced
cervical and laryngeal tumors.19,25 A previous cross-sectional study found no association between
HPV status and CD1 expression status in esophageal biopsy specimens from patients representing
the Barrett esophagus low- and high-grade dysplasia adenocarcinoma sequence.14 Plausible reasons
include the fact that most of the dysplastic specimens were low grade and the sample size of the
Barrett HGD and EAC cohorts was relatively small.
Strengths and Limitations
Care was undertaken tominimize cross-contamination of samples as described in theMethods
section and thus avoid false-positive HPV DNA detection. Central reporting of slides was undertaken
by academic gastrointestinal pathologists, which is an added strength of this study.
The study has limitations. The sample size was small, and the retrospective nature and case-
control design of the study introduce biases involving selection, information, observation, and
confounding. Recruitment of patients from secondary and tertiary medical centers further
exacerbates selection bias; however, the unknown HPV status at the time of enrollment and
treatment decisionmitigated both selection and observer bias. Blinding the scientists and
pathologists to the patients’ clinical, virologic, and biomarker status as well as treatment outcome
minimizedmeasurement bias. Confounding was reduced with adjustment for potential confounders
in themultivariate analysis.
There also was a problemwith tissue sampling. Multiple biopsies from the Barrett HGD and EAC
segment were unavailable to assess for circumferential and longitudinal discordance for viral and
protein marker detection. Microdissection of tissue specimensmay have increased the yield of
lesional cells for analysis. Immunohistochemistry analysis is subjective and lacks uniform scoring
systems. Some tissue specimens usedwere obtainedmore than 10 years before this study, which can
result in DNA invalidity. Specifically, given the age of some of the samples, the MY09/MY11 primers
used in the nested PCRmight not be able to amplify the 450–base pair target area.
Conclusions
This study’s findings suggest that low expression of CD1 appears to be an independent prognostic
marker in Barrett HGD and EAC. Tumor HPV status in combinationwith pRb, CD1, MCM2, or Ki-67 has
a significant association with survival, disease relapse and progression, and disease-specific death.
Further confirmatory studies are required before clinical use of CD1 and HPV status as prognostic
biomarkers.
If these findings are confirmed by others, then understanding the underlying mechanism that
underpins these differential survival outcomes betweenHPV-positive andHPV-negative Barrett HGD
and EACwould be paramount. This understanding could translate into improved treatment selection
for these patients based on HPV status.
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eTable 3. Comparison of Survival, Disease Relapse, Progression and Site of Failure in Low CD1 or High CD1
Expression Patients Stratified by HPV Status
eTable 4. Comparison of Survival, Disease Relapse, Progression and Site of Failure in LowMCM2 or HighMCM2
Expression Patients Stratified by HPV Status
eTable 5. Comparison of Survival, Disease Relapse, Progression and Site of Failure in Ki-67 Positive or Negative
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